RxDoctor Payments DataLook up a doctor →

Philip Nicol, MD

Internal Medicine · Murrells Inlet, SCNPI 1417996554

Payments from drug & device makers

$782,242in general payments, 2019–2025

Across 616 payments — averaging $1269.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$434K
  • Novo Nordisk AS$149K
  • Sanofi US Services Inc.$121K
  • Bayer$48K
  • Janssen Research & Development, LLC$24K
  • Eli Lilly$6K
  • plus $1K from 14 others

What the payments were for

  • Travel & lodging$1,04941%
  • Food & beverage$1,49158%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$782,242 in reported general payments places this provider in the 95th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$129,197
Medicare patients
400
Services billed
2,620

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide335$511,619
TrulicityDulaglutide125$196,412
JardianceEmpagliflozin142$175,611
MounjaroTirzepatide87$109,883
JanuviaSitagliptin Phosphate65$86,593
Tresiba Flextouch U-100Insulin Degludec96$64,930
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog73$57,200
EliquisApixaban42$56,803
FarxigaDapagliflozin Propanediol30$45,991
Tresiba Flextouch U-200Insulin Degludec29$32,328
TradjentaLinagliptin30$27,591
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog40$24,144
Lantus SolostarInsulin Glargine,hum.Rec.Anlog133$20,697
XareltoRivaroxaban12$18,550
RybelsusSemaglutide17$18,170

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$263$534,375364 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$57$312,651229 claims
MerckJanuvia, Janumet$27$96,36379 claims
PfizerEliquis$30$56,80342 claims
AstraZenecaFarxiga$46$45,99130 claims
Johnson & JohnsonXarelto$141$18,55012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Murrells Inlet

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →